139 related articles for article (PubMed ID: 11012581)
1. Gigantism due to growth hormone excess in a boy with optic glioma.
Drimmie FM; MacLennan AC; Nicoll JA; Simpson E; McNeill E; Donaldson MD
Clin Endocrinol (Oxf); 2000 Oct; 53(4):535-8. PubMed ID: 11012581
[TBL] [Abstract][Full Text] [Related]
2. Growth hormone excess in children with neurofibromatosis type-1 and optic glioma.
Cambiaso P; Galassi S; Palmiero M; Mastronuzzi A; Del Bufalo F; Capolino R; Cacchione A; Buonuomo PS; Gonfiantini MV; Bartuli A; Cappa M; Macchiaiolo M
Am J Med Genet A; 2017 Sep; 173(9):2353-2358. PubMed ID: 28631895
[TBL] [Abstract][Full Text] [Related]
3. Optic glioma and precocious puberty in a girl with neurofibromatosis type 1 carrying an R681X mutation of NF1: case report and review of the literature.
Kocova M; Kochova E; Sukarova-Angelovska E
BMC Endocr Disord; 2015 Dec; 15():82. PubMed ID: 26666878
[TBL] [Abstract][Full Text] [Related]
4. Pituitary gigantism caused by growth hormone excess from infancy.
Gelber SJ; Heffez DS; Donohoue PA
J Pediatr; 1992 Jun; 120(6):931-4. PubMed ID: 1593354
[TBL] [Abstract][Full Text] [Related]
5. Precocious puberty associated with neurofibromatosis and optic gliomas. Treatment with luteinizing hormone releasing hormone analogue.
Laue L; Comite F; Hench K; Loriaux DL; Cutler GB; Pescovitz OH
Am J Dis Child; 1985 Nov; 139(11):1097-100. PubMed ID: 3933329
[TBL] [Abstract][Full Text] [Related]
6. Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism--effect of octreotide therapy.
Schoof E; Dörr HG; Kiess W; Lüdecke DK; Freitag E; Zindel V; Rascher W; Dötsch J
Horm Res; 2004; 61(4):184-9. PubMed ID: 14739526
[TBL] [Abstract][Full Text] [Related]
7. Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma.
Müssig K; Gallwitz B; Honegger J; Strasburger CJ; Bidlingmaier M; Machicao F; Bornemann A; Ranke MB; Häring HU; Petersenn S
Exp Clin Endocrinol Diabetes; 2007 Mar; 115(3):198-202. PubMed ID: 17427111
[TBL] [Abstract][Full Text] [Related]
8. Suppression of GH secretion in pituitary gigantism by continuous subcutaneous octreotide infusion in a pubertal boy.
Näntö-Salonen K; Koskinen P; Sonninen P; Toppari J
Acta Paediatr; 1999 Jan; 88(1):29-33. PubMed ID: 10090543
[TBL] [Abstract][Full Text] [Related]
9. Precocious and accelerated puberty in children with neurofibromatosis type 1: results from a close follow-up of a cohort of 45 patients.
Pinheiro SL; Maciel J; Cavaco D; Figueiredo AA; Damásio IL; Donato S; Passos J; Simões-Pereira J
Hormones (Athens); 2023 Mar; 22(1):79-85. PubMed ID: 36269545
[TBL] [Abstract][Full Text] [Related]
10. Reversible Growth Hormone Excess in Two Girls with Neurofibromatosis Type 1 and Optic Pathway Glioma.
Bruzzi P; Sani I; Albanese A
Horm Res Paediatr; 2015; 84(6):414-22. PubMed ID: 26488470
[TBL] [Abstract][Full Text] [Related]
11. Congenital gigantism due to growth hormone-releasing hormone excess and pituitary hyperplasia with adenomatous transformation.
Zimmerman D; Young WF; Ebersold MJ; Scheithauer BW; Kovacs K; Horvath E; Whitaker MD; Eberhardt NL; Downs TR; Frohman LA
J Clin Endocrinol Metab; 1993 Jan; 76(1):216-22. PubMed ID: 8421089
[TBL] [Abstract][Full Text] [Related]
12. Pegvisomant treatment in a 4-year-old girl with neurofibromatosis type 1.
Main KM; Sehested A; Feldt-Rasmussen U
Horm Res; 2006; 65(1):1-5. PubMed ID: 16269873
[TBL] [Abstract][Full Text] [Related]
13. The effect of long-acting analog of luteinizing hormone-releasing hormone on growth hormone secretory dynamics in children with precocious puberty.
DiMartino-Nardi J; Wu R; Fishman K; Saenger P
J Clin Endocrinol Metab; 1991 Oct; 73(4):902-6. PubMed ID: 1909708
[TBL] [Abstract][Full Text] [Related]
14. High-Dose Intravenous Vitamin C Treatment of a Child with Neurofibromatosis Type 1 and Optic Pathway Glioma: A Case Report.
Mikirova N; Hunnunghake R; Scimeca RC; Chinshaw C; Ali F; Brannon C; Riordan N
Am J Case Rep; 2016 Oct; 17():774-781. PubMed ID: 27773919
[TBL] [Abstract][Full Text] [Related]
15. Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: a longitudinal study.
Carmi D; Shohat M; Metzker A; Dickerman Z
Pediatrics; 1999 Jun; 103(6 Pt 1):1257-62. PubMed ID: 10353939
[TBL] [Abstract][Full Text] [Related]
16. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl.
Rix M; Laurberg P; Hoejberg AS; Brock-Jacobsen B
Eur J Endocrinol; 2005 Aug; 153(2):195-201. PubMed ID: 16061823
[TBL] [Abstract][Full Text] [Related]
17. Suppression of puberty with long-acting goserelin (Zoladex-LA): effect on gonadotrophin response to GnRH in the first treatment cycle.
Trueman JA; Tillmann V; Cusick CF; Foster P; Patel L; Hall CM; Price DA; Clayton PE
Clin Endocrinol (Oxf); 2002 Aug; 57(2):223-30. PubMed ID: 12153601
[TBL] [Abstract][Full Text] [Related]
18. Height prognosis of children with true precocious puberty and growth hormone deficiency: effect of combination therapy with gonadotropin releasing hormone agonist and growth hormone.
Cara JF; Kreiter ML; Rosenfield RL
J Pediatr; 1992 May; 120(5):709-15. PubMed ID: 1533661
[TBL] [Abstract][Full Text] [Related]
19. The effect of luteinizing hormone-releasing hormone analog for central precocious puberty on growth hormone (GH) and GH-binding protein.
DiMartino-Nardi J; Wu R; Varner R; Wong WL; Saenger P
J Clin Endocrinol Metab; 1994 Mar; 78(3):664-8. PubMed ID: 8126139
[TBL] [Abstract][Full Text] [Related]
20. Presentation and evolution of organic central precocious puberty according to the type of CNS lesion.
Trivin C; Couto-Silva AC; Sainte-Rose C; Chemaitilly W; Kalifa C; Doz F; Zerah M; Brauner R
Clin Endocrinol (Oxf); 2006 Aug; 65(2):239-45. PubMed ID: 16886967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
